Welcome to our dedicated page for Aditxt SEC filings (Ticker: ADTX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Aditxt, Inc. filings document the company’s life sciences platform, its common stock capital structure, and material events affecting its operating subsidiaries and public-company status. Recent Form 8-K reports cover the completed acquisition of Ignite Proteomics, related financial statements and pro forma information, senior unsecured promissory notes, at-the-market offering capacity, and Nasdaq listing-compliance matters.
Proxy materials and meeting reports describe board elections, auditor ratification, executive-compensation votes, reverse stock split authority, and other stockholder matters. The filing record also includes disclosures on preferred stock issued in acquisition consideration, equity financing arrangements, governance approvals, and risks associated with maintaining exchange listing standards.
Aditxt, Inc. reported that Nasdaq has granted extra time to regain compliance with Nasdaq Listing Rule 5550(b), which requires minimum stockholders’ equity of $2,500,000, a market value of listed securities of $35,000,000, or net income of $500,000 in certain periods.
The extension depends on Aditxt completing financing transactions and, on or before May 15, 2026, filing a public report with the SEC and Nasdaq explaining how it believes it satisfies the stockholders’ equity requirement, potentially including a recent pro forma balance sheet.
If Aditxt does not show compliance with the rule when it files its periodic report for the period ending June 30, 2026, its shares may be delisted from Nasdaq, although the company would be able to appeal any delisting determination to a Nasdaq Hearings Panel. The company cautions there is no assurance it will regain or maintain compliance.
Aditxt, Inc. is calling a virtual special stockholder meeting on January 30, 2026 to approve several significant capital and governance changes. Stockholders will vote on approvals related to prior financings, including issuances tied to Series A-1 and Series C-1 convertible preferred stock and multiple warrant agreements, as required by Nasdaq rules. They are also being asked to adopt a 2025 Employee Stock Purchase Plan reserving 200,000 shares and to increase the 2021 Omnibus Equity Incentive Plan share pool to 350,000 shares, which the company states would equal about 19.7% of its common stock. Additional proposals would change the corporate name to “bitXbio, Inc.”, authorize the board to implement a reverse stock split at a ratio between one-for-five (1:5) and one-for-two hundred fifty (1:250) within one year, and permit adjournment of the meeting to solicit more proxies if needed. Holders of Aditxt’s 1,776,023 outstanding common shares as of December 5, 2025 are entitled to one vote per share.
The company filed a prospectus supplement to increase the capacity of its at-the-market common stock offering to up to $20,000,000 in aggregate gross sales, not including shares previously sold, under its existing agreement with H.C. Wainwright & Co., LLC as sales agent.
Previously, the company had registered up to $35,000,000 of common stock for sales under this program, later reduced to $11,840,454, and it has already sold 1,370,607 shares for aggregate gross proceeds of $17,771,951 under prior prospectus supplements. The supplement also notes that the company is currently no longer subject to the offering limits in General Instruction I.B.6 of Form S-3, and that its common stock trades on the Nasdaq Capital Market under the symbol ADTX, where the last reported sale price was $2.24 per share on December 12, 2025.
Aditxt, Inc. (ADTX) reported an insider transaction by its Chief M&A Officer on a Form 4. On 11/25/2025, the officer sold 1 share of Aditxt common stock at a price of $3.2 per share in a transaction coded "S" for sale. After this small tax-related sale, the reporting person held 0 shares of Aditxt common stock directly. The explanation notes that the share was sold for tax-related purposes.
Aditxt, Inc. reported that on November 18, 2025 it issued a press release describing its bitXbio™ strategy and announcing the filing of a preliminary proxy statement on Schedule 14A for a special meeting of stockholders. The proxy statement includes proposals related to the Company’s Employee Stock Purchase Plan and a non-binding advisory vote on amending its Certificate of Incorporation to change the corporate name from “Aditxt, Inc.” to “bitXbio, Inc.” The press release is included as Exhibit 99.1 and incorporated by reference.
Aditxt, Inc. (ADTX) reported very limited revenue and heavy losses in its latest quarter. For the nine months ended September 30, 2025, sales were only $2,770, while the company recorded a net loss of $37,555,792 and used $16,442,686 of cash in operating activities.
Cash on hand was just $163,041, against total liabilities of $20,658,817, resulting in a stockholders’ equity deficit of $8,859,178. Management states there is substantial doubt about Aditxt’s ability to continue as a going concern and notes constraints on raising capital under the Form S-3 “baby shelf” limitation.
A major driver of the loss was a $23,001,919 impairment on its Evofem F-1 Preferred Stock investment, reducing the Evofem-related balance to $7,051,933. The company also faces high-cost debt, lease payment arrears, multiple recent reverse stock splits, and warns that a potential Nasdaq delisting could further hurt liquidity, valuation, and access to financing.
Aditxt, Inc. (ADTX) submitted a Form 12b-25 to notify that its Form 10-Q for the quarter ended September 30, 2025 will be filed late. The company states that the compilation, dissemination and review of the information required for the quarterly report created time constraints that made a timely filing impracticable without undue hardship and expense. Aditxt states that it undertakes the responsibility to file the Form 10-Q no later than 5 days after its original due date under the Rule 12b-25 extension framework.
Aditxt, Inc. (ADTX) approved a 1-for-113 reverse stock split of its issued and outstanding common stock. The split becomes effective at 4:01 p.m. Eastern Time on October 31, 2025, and shares will begin trading on a split-adjusted basis on November 3, 2025. The stated purpose is to bring the company into compliance with Nasdaq’s minimum bid price requirement.
The reverse split does not change the number of authorized shares or the $0.001 par value. Exercise prices and share amounts for outstanding options, restricted stock units, warrants, and plan reserves will be adjusted proportionately, and any fractional shares will be rounded up to the next whole share. The stock will continue trading under the ticker ADTX, and has been assigned a new CUSIP number 007025885.
Aditxt, Inc. reported that Evofem Biosciences terminated the parties’ Amended and Restated Agreement and Plan of Merger, effective immediately. Evofem cited Section 8.1(b)(ii) (the end date having passed) and Section 8.1(b)(iv) (failure to obtain shareholder approval at the October 20, 2025 special meeting) as the bases for termination.
The company stated that no termination fee or other early-termination penalty is payable by Aditxt in connection with a termination under those sections. Certain provisions survive, including the parties’ Non‑Disclosure Agreement dated October 23, 2023. Aditxt is reviewing the notice and evaluating its rights and remedies under the Merger Agreement and applicable law.
Aditxt, Inc. appointed Christopher J. Porcelli as its General Counsel, Chief People Officer and Corporate Secretary, effective September 30, 2025. Under his offer letter, he will receive an annual base salary of $350,000, with employment on an at-will basis and eligibility to participate in employee benefit plans generally available to senior executives. The offer also includes an initial equity award under Aditxt’s equity incentive plan, subject to Compensation Committee approval, which is expected to vest over three years based on continued service. The company plans to file the full offer letter as an exhibit to its next periodic report.